The development of targeted medicine has greatly expanded treatment options and spurred
new research avenues in cancer therapeutics, with monoclonal antibodies (mAbs) emerging …

The term bispecific antibody (bsAb) is used to describe a large family of molecules designed
to recognize two different epitopes or antigens. BsAbs come in many formats, ranging from …

Recent advances in cancer immunotherapy using monoclonal antibodies have dramatically
revolutionized the therapeutic strategy against advanced malignancies, inspiring the …

The recent advances in the field of immuno-oncology have dramatically changed the
therapeutic strategy against advanced malignancies. Bispecific antibody-based …

Bispecific molecules redirecting the cytotoxicity of T-cells are a growing class of therapeutics
with numerous molecules being tested in clinical trials. However, it has been a long way …

The concepts for T-cell redirecting bispecific antibodies (TRBAs) and chimeric antigen
receptor (CAR)-T cells are both at least 30 years old but both platforms are just now coming …

With almost 20 million new cases per year, cancer constitutes one of the most important
challenges for public health systems. Unlike traditional chemotherapy, targeted anti-cancer …

Targeted therapy and immunotherapy have become mainstream in cancer treatment.
However, only patient subsets benefit from these expensive therapies, and often responses …

In the last decade, cancer immunotherapies have produced impressive therapeutic results.
However, the potency of immunotherapy is tightly linked to immune cell infiltration within the …

The costimulation of immune cells using first-generation anti-4-1BB monoclonal antibodies
(mAbs) has demonstrated anti-tumor activity in human trials. Further clinical development …